clinical trial · NCT03529110
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Daiichi Sankyo·phase3·active not recruiting·n = 524
Breast CancerTrastuzumab deruxtecan (T-DXd)Ado-trastuzumab emtansine (T-DM1)
brief summary
This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
started
Aug 9, 2018
primary completion
May 21, 2021
completion
Jul 30, 2026
last updated
Oct 21, 2025
official title
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol